莫西沙星联合尿激酶治疗包裹性结核性胸膜炎胸膜增厚疗效分析

Moxifloxacin Combined Urokinase in Treatment of Parcel Tuberculous Pleurisy Pleural Thickening Effect Analysis

目的分析包裹性结核性胸膜炎胸膜增厚患者实施莫西沙星、尿激酶联合疗法的效果。方法从该院2012年1月—2015年6月收治的包裹性结核性胸膜炎胸膜增厚患者中随机抽选70例,按入院编号的单双数分成对照组和研究组,对照组患者实施尿激酶疗法治疗,研究组患者实施莫西沙星、尿激酶联合疗法治疗,观察治疗后胸膜厚度、用力肺活量、第1秒用力呼吸容积等指标。结果研究组、对照组患者经由不同的疗法治疗后,研究组缓解率91.42%,对照组缓解率71.43%,差异有统计学意义(P<0.05)。结论临床给予包裹性结核性胸膜炎胸膜增厚患者莫西沙星、尿激酶联合疗法作用显著,可提高疗效,改善生活现状,值得借鉴。

Objective To analyze encapsulated tuberculous pleural thickening for patients with moxifloxacin, urokinase combination therapy results. Methods From January 2012 to June 2015 were parcel tuberculous pleurisy pleural thickening 2.5in patients randomly selected 70 cases, according to the admission number of single dual divided into control group and study group, control the implementation of urokinase therapy group. Patients in the study group implementation of moxifloxacin, pleural thickness, forced vital capacity, forced expiratory volume in 1 second indexes were observed after treatment. Results The study group and the control group were treated with different therapy, the remission rate of the study group was 91.42%, and the remission rate was 71.43%, the difference was statistically significant（P〈0.05）. Conclusion The clinical administration of encapsulated tuberculous pleurisy pleural thickening in patients with moxifloxacin, urokinase combination therapy a significant effect, can improve efficacy, to improve the situation of life, it is worth learning from.